Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Involvement of 5-lipoxygenase (5-LO) pathway in eosinophil chemotaxis to acetylsalicylic acid (ASA) in aspirin-sensitive and healthy non-allergic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 382s Year: 2002
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011
5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Effect of a thrombin inhibitor on murine bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
15-LOXb is the enzymatic source of aspirin induced 15-HETE generation in aspirin-sensitive patients Source: Eur Respir J 2005; 26: Suppl. 49, 342s Year: 2005
Effects of 5-lipoxygenase inhibitor on airway responses to inhaled organic dust in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 307s Year: 2002
Higher expression of lipoxygenase and cyclooxygenase pathways in bronchial than alveolar lavage from allergic asthmatics Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021
Clinical efficacy of leukotriene antagonist in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
Eosinophils chemotaxis to acetylsalicylic acid (ASA) is inhibited in aspirin-sensitive (ASA-S) asthmatics - possible role for lymphocyte involvement Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010